Literature DB >> 6609202

Human B lymphocytes show greater susceptibility to H2O2 toxicity than T lymphocytes.

C M Farber, L F Liebes, D N Kanganis, R Silber.   

Abstract

Lymphocytes from patients with chronic lymphocytic leukemia (CLL) and from normal subjects were incubated with a glucose-glucose oxidase hydrogen peroxide (H2O2) generating system to study the effect of oxidant stress on these cells. Within 4 hr, 90% of normal but only 21% of CLL lymphocytes remained viable. When normal and CLL preparations enriched in B or T cells were exposed to H2O2, B lymphocytes from both groups were highly susceptible to oxidative damage while T lymphocytes were relatively resistant. The H2O2 scavenger catalase prevented the cytotoxicity. The present work identifies the human B lymphocyte as a cell that should be a suitable target for selective killing by H2O2-generating systems.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609202

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.

Authors:  Sabyasachi Biswas; Xiaobin Zhao; Andrew P Mone; Xiaokui Mo; Melissa Vargo; David Jarjoura; John C Byrd; Natarajan Muthusamy
Journal:  Leuk Res       Date:  2010-02-19       Impact factor: 3.156

2.  Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

Authors:  Neil E Kay; Tait D Shanafelt; Ann K Strege; Yean K Lee; Nancy D Bone; Azra Raza
Journal:  Leuk Res       Date:  2007-01-22       Impact factor: 3.156

3.  Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism.

Authors:  R F Dielschneider; H Eisenstat; S Mi; J M Curtis; W Xiao; J B Johnston; S B Gibson
Journal:  Leukemia       Date:  2015-02-23       Impact factor: 11.528

4.  Ultraviolet-A (UVA-1) radiation suppresses immunoglobulin production of activated B lymphocytes in vitro.

Authors:  M C A Polderman; C van Kooten; N P M Smit; S W A Kamerling; S Pavel
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

5.  Role of nicotinamide adenine dinucleotide and adenosine triphosphate in glucocorticoid-induced cytotoxicity in susceptible lymphoid cells.

Authors:  N A Berger; S J Berger; D C Sudar; C W Distelhorst
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

6.  Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.

Authors:  Angelo Agathanggelou; Victoria J Weston; Tracey Perry; Nicholas J Davies; Anna Skowronska; Daniel T Payne; John S Fossey; Ceri E Oldreive; Wenbin Wei; Guy Pratt; Helen Parry; David Oscier; Steve J Coles; Paul S Hole; Richard L Darley; Michael McMahon; John D Hayes; Paul Moss; Grant S Stewart; A Malcolm R Taylor; Tatjana Stankovic
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

7.  Cutting edge: NADPH oxidase modulates MHC class II antigen presentation by B cells.

Authors:  Victoria L Crotzer; Juan D Matute; Andrés A Arias; Heng Zhao; Lawrence A Quilliam; Mary C Dinauer; Janice S Blum
Journal:  J Immunol       Date:  2012-09-14       Impact factor: 5.422

8.  Resistance of human tumor cells in vitro to oxidative cytolysis.

Authors:  J O'Donnell-Tormey; C J DeBoer; C F Nathan
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

9.  Neutrophil-derived Oxidants and Proteinases as Immunomodulatory Mediators in Inflammation.

Authors:  V Witko-Sarsat; B Descamps-Latscha
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

10.  Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia.

Authors:  Walaa Darwiche; Cathy Gomila; Hakim Ouled-Haddou; Marie Naudot; Cécile Doualle; Pierre Morel; Florence Nguyen-Khac; Loïc Garçon; Jean-Pierre Marolleau; Hussein Ghamlouch
Journal:  J Exp Clin Cancer Res       Date:  2020-10-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.